Navigation Links
Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
Date:9/14/2007

HAMBURG, Germany, Sept. 14 /PRNewswire/ -- Indivumed announces today that a service agreement with Roche Diagnostics GmbH was signed. Within this agreement Indivumed will apply its automated immunohistochemistry service platform for analyzing various biomarkers and drug targets in the area of oncology. Indivumed will provide for this project a selection of tumor tissue sections from its tumor biobank as well as specifically collected clinical samples. The analysis of specific biomarkers and drug targets should enable Roche to efficiently develop novel targeted therapies for cancer.

Indivumed is a privately held biotech company focused on the generation, characterization and analysis of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany with a subsidiary in Kensington, Maryland, USA, Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area. Indivumed's current tumor biobank of over 6500 patient-cases, collected with a mean cold ischemia time of less than eight minutes, serves as a resource for Indivumed's internal cancer research in biomarkers and primary cell drug screening as well as for the use of pharmaceutical and biopharma partners through tumor biobank access and IHC services.


'/>"/>
SOURCE Indivumed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. CDW buyer supports Berbee growth plans
2. Tech center supports energy-saving device for heat-treating plants
3. Inacom Supports Blackhawk Technology Mentor Program
4. Computer Card Supports Solo Doctor
5. Federal Funding Supports Small Business Innovation
6. Advantages of Roche Applied Science amplification products
7. Roche Diagnostics Corporation
8. Roche Diagnostics Corporation
9. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
10. Prodesse enters patent agreement with Roche
11. A prognosis for GE and Abbott Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):